An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.
about
T cell recognition of weak ligands: roles of signaling, receptor number, and affinitySevere anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitusThe Role of Chemokines in Shaping the Balance Between CD4(+) T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer DiseasesTempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cellsInstant effect of soluble antigen on effector T cells in peripheral immune organs during immunotherapy of autoimmune encephalomyelitisA GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APCMolecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune diseaseManipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptidesMast cells in autoimmune disease.Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy.Immunogenicity to biologics: mechanisms, prediction and reduction.Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis.Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.Antigen-presenting cells and tolerance induction.Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination.Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23Antigen-based immune modulation: DNA vectors and beyond.Attenuation of Th1 effector cell responses and susceptibility to experimental allergic encephalomyelitis in histamine H2 receptor knockout mice is due to dysregulation of cytokine production by antigen-presenting cells.Gene therapy in autoimmune, demyelinating disease of the central nervous system.Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion.Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MSCritical role for prokineticin 2 in CNS autoimmunity.Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.Preferential Interactions and the Effect of Protein PEGylation.Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance.Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy?Immune modulating peptides for the treatment and suppression of multiple sclerosis.Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year.Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor.Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis.Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis.Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.A Journey in Science: The Privilege of Exploring the Brain and the Immune System.Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis.L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart.
P2860
Q24626152-8A243B81-1E85-495E-AD68-677425239B35Q24792991-59E9350F-35B0-4DF1-B02A-2BF2E36C45FFQ26773127-699FD671-0530-4565-BE4F-5EF1D378B54CQ26851647-1ED13E9D-5EE5-4096-85F3-4D5ADD6179ACQ30478895-FFDE7951-1A99-447C-B3DD-762906D0ACD0Q33694528-E40BC18F-F3B3-4F01-A864-70D1C8F8071AQ33753720-C62D4F2D-10EC-4A0C-8A97-09C2DB9A9494Q33785953-1C8403E6-E1D5-4904-8F14-6A069D422826Q33838467-3DCBA524-9FA2-4955-8B9E-B285BDC7AC85Q33892424-98F55472-BE35-4B1F-BFDE-C5B2F8B56E6DQ34091080-90E209FB-2B58-416B-98B3-A899EC3446E4Q34165916-5579D912-2B28-4A43-A087-9DCD3AE3DF83Q34205503-D3C3802E-A62B-42BF-B0B5-BC5E6E769CA1Q34296526-FD02F1E3-84DF-42C2-B38B-82A4A9EDF465Q34355706-5E989053-4C18-4508-8542-0D261672DAB7Q34567730-3DA67B1B-7D09-47F5-9945-D48274D321D6Q34625275-F8E4026B-2EFC-4BC8-A101-A9B89D20EB80Q34762330-A97E7002-2F1A-414C-A879-395CD792FE5DQ34797949-56D4DB34-2F75-43E1-A6D0-5360296AC0E4Q35040861-7CE29633-7B45-477A-B8E2-C25E765B1B80Q35096050-1AD49317-CEA1-4207-9253-60B87BCBEE83Q35122159-2A8CFC7D-E678-4548-8722-6DFDD4ED15ECQ35125791-98CA81B4-6E32-4E18-A5CE-9D8DB8EFDDE2Q35179832-5A187B73-9618-45F9-914D-CCC41A4F70D2Q35409577-886C4FC8-63A0-4026-BABE-85B4BB4E54BEQ35637379-EAB641F4-6668-432A-B009-F811485F03BFQ35730064-488BDB71-46B3-43B6-BD6A-5891D7D7101DQ35792672-6721B5E9-A07C-4ADD-9F84-FCDAB75CDA72Q35839611-433A41E7-CF6A-466F-8084-ED524E2E2E28Q36013705-21D34A92-49C3-478A-9236-B9D1F2CD23B4Q36151968-165AB0F4-9622-4405-BBAF-198B54A5DBCDQ36327367-63A5F50C-F243-4CDB-8ACE-A7D8D8A52D58Q36370956-E510F948-95C4-46E5-A61D-C1480201CC5BQ36403038-887DFD7D-C6BC-4265-8886-07AAC9F93FD0Q36800398-3526F42E-5411-490C-A0CF-0882DFFA701BQ36914452-0155EBA6-1FC9-4F52-80BA-7C72AA8A2CAFQ37002699-DEBE7065-B82D-4422-8844-855D3C899DBFQ37217037-9E70101D-CCD8-4856-B45F-35A666F5223BQ37235161-3EAE80A6-F5FD-49D1-B451-27109F527699Q37277258-54E431AF-FA48-4CE6-88A2-ECE7BE28F973
P2860
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.
@ast
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.
@en
type
label
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.
@ast
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.
@en
prefLabel
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.
@ast
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.
@en
P2093
P2860
P356
P1433
P1476
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.
@en
P2093
Mitchell D
Steinman L
Wedemeyer J
P2860
P304
P356
10.1038/85266
P407
P577
2001-03-01T00:00:00Z